May 30, 2018

Symphogen further strengthens its immuno-oncology pipeline by advancing into two additional clinical trials

- Seventh program to enter clinical development at Symphogen.

- Symphogen’s antibody platform is now validated for immuno-oncology to deliver unique monoclonal antibody products.
Read more
November 30, 2017

Symphogen receives milestone payment for initiation of Phase 1b trial in infectious disease

Symphogen, a private clinical late-stage antibody oncology-focused company with a novel and differentiated antibody mixture pipeline, announced today that the company has received a $5 million milestone payment from Genentech, a member of the Roche Group, triggered by the initiation of a Phase 1b clinical trial evaluating DSTA4637S, an investigational medicine containing a Symphogen-generated antibody conjugated to an antibiotic agent for the potential treatment of Staphylococcus aureus (S.aureus) infections.
Read more
September 11, 2017

Symphogen presents detailed results for randomized Phase 2 study with Sym004 in refractory metastatic colorectal cancer at ESMO 2017 Congress

Symphogen, an advanced clinical-stage antibody company focused on oncology, today announced detailed results from its randomized Phase 2 study with Sym004, a synergistic mAb mixture targeting epidermal growth factor receptor (EGFR), compared to investigator-choice chemotherapy or best-supportive-care, in patients with advanced metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR monoclonal antibodies (mAbs).
Read more
August 31, 2017

Symphogen presents Sym004 Phase 2 data at ESMO 2017 Congress

Symphogen, an advanced clinical stage antibody company focused on oncology, announces today that the promising data from its Phase 2 study with Sym004, a mAb mixture targeting EGFR, has been selected for oral presentation on 11 September 2017 at the European Society for Medical Oncology (ESMO) 2017 Congress, taking place from 8-12 September 2017, in Madrid, Spain.
Read more
September 15, 2016

Symphogen Names New Chief Financial Officer

Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that Jesper Bramming has joined Symphogen as its new Chief Financial Officer, filling the position vacated by Martin Olin, M.Sc., EMBA, who was promoted to Chief Executive Officer and member of the Board of Directors.
Read more
August 18, 2016

Symphogen’s founding CEO Kirsten Drejer steps down and becomes Executive Director

Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that Kirsten Drejer, M.Sc., Ph. D., Co-founder, Chief Executive Officer and Director will transition from an executive operational role to an independent member of the Board of Directors. In parallel, Martin Olin, M.Sc., E*MBA, now Chief Financial Officer, has been promoted effective 1st September to Chief Executive Officer and member of the Board of Directors. Kirsten Drejer is proposed to be elected to the Board of Directors as an independent member and will, through a transition period, be a working Board member assisting Martin Olin.
Read more
May 11, 2016

Symphogen announces the appointment of Jeffrey H. Buchalter and Christoffer Søderberg as Non-Executive Directors

Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today the appointment to the company's Board of Directors two new Non-Executive Directors: Mr. Jeffrey H. Buchalter and Mr. Christoffer Søderberg, effective 10 May 2016.

Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today the appointment to the company's Board of Directors two new Non-Executive Directors: Mr. Jeffrey H. Buchalter and Mr. Christoffer Søderberg, effective 10 May 2016.
Read more
Read more about our ownership